Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin - PubMed (original) (raw)
Randomized Controlled Trial
. 2008 Mar 5;299(9):1036-45.
doi: 10.1001/jama.299.9.1036.
Robert Wallace, Garnet L Anderson, Aaron Aragaki, Shirley A A Beresford, Robert Brzyski, Rowan T Chlebowski, Margery Gass, Andrea LaCroix, JoAnn E Manson, Ross L Prentice, Jacques Rossouw, Marcia L Stefanick; WHI Investigators
Collaborators, Affiliations
- PMID: 18319414
- DOI: 10.1001/jama.299.9.1036
Free article
Randomized Controlled Trial
Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin
Gerardo Heiss et al. JAMA. 2008.
Free article
Abstract
Context: The Women's Health Initiative (WHI) trial of estrogen plus progestin vs placebo was stopped early, after a mean 5.6 years of follow-up, because the overall health risks of hormone therapy exceeded its benefits.
Objective: To report health outcomes at 3 years (mean 2.4 years of follow-up) after the intervention was stopped.
Design, setting, and participants: The intervention phase was a double-blind, placebo-controlled, randomized trial of conjugated equine estrogens (CEE) 0.625 mg daily plus medroxyprogesterone acetate (MPA) 2.5 mg daily, in 16,608 women aged 50 through 79 years, recruited by 40 centers from 1993 to 1998. The postintervention phase commenced July 8, 2002, and included 15 730 women.
Main outcome measures: Semi-annual monitoring and outcomes ascertainment continued per trial protocol. The primary end points were coronary heart disease and invasive breast cancer. A global index summarizing the balance of risks and benefits included the 2 primary end points plus stroke, pulmonary embolism, endometrial cancer, colorectal cancer, hip fracture, and death due to other causes.
Results: The risk of cardiovascular events after the intervention was comparable by initial randomized assignments, 1.97% (annualized rate) in the CEE plus MPA (343 events) and 1.91% in the placebo group (323 events). A greater risk of malignancies occurred in the CEE plus MPA than in the placebo group (1.56% [n = 281] vs 1.26% [n = 218]; hazard ratio [HR], 1.24; 95% confidence interval [CI], 1.04-1.48). More breast cancers were diagnosed in women who had been randomly assigned to receive CEE plus MPA vs placebo (0.42% [n = 79] vs 0.33% [n = 60]; HR, 1.27; 95% CI, 0.91-1.78) with a modest trend toward a lower HR during the follow-up after the intervention. All-cause mortality was somewhat higher in the CEE plus MPA than in the placebo group (1.20% [n = 233] vs 1.06% [n = 196]; HR, 1.15; 95% CI, 0.95-1.39). The global index of risks and benefits was unchanged from randomization through March 31, 2005 (HR, 1.12; 95% CI, 1.03-1.21), indicating that the risks of CEE plus MPA exceed the benefits for chronic disease prevention.
Conclusions: The increased cardiovascular risks in the women assigned to CEE plus MPA during the intervention period were not observed after the intervention. A greater risk of fatal and nonfatal malignancies occurred after the intervention in the CEE plus MPA group and the global risk index was 12% higher in women randomly assigned to receive CEE plus MPA compared with placebo.
Trial registration: clinicaltrials.gov Identifier: NCT00000611.
Comment in
- Colorectal cancer in women after stopping postmenopausal hormone therapy.
Odell TW. Odell TW. JAMA. 2008 Jun 18;299(23):2744; author reply 2744-5. doi: 10.1001/jama.299.23.2744-a. JAMA. 2008. PMID: 18559997 No abstract available. - Risk for cancer was still increased over 2 years after stopping hormone therapy.
Cheung AM. Cheung AM. ACP J Club. 2008 Aug 19;149(2):11. ACP J Club. 2008. PMID: 18710184 No abstract available.
Similar articles
- Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials.
Manson JE, Chlebowski RT, Stefanick ML, Aragaki AK, Rossouw JE, Prentice RL, Anderson G, Howard BV, Thomson CA, LaCroix AZ, Wactawski-Wende J, Jackson RD, Limacher M, Margolis KL, Wassertheil-Smoller S, Beresford SA, Cauley JA, Eaton CB, Gass M, Hsia J, Johnson KC, Kooperberg C, Kuller LH, Lewis CE, Liu S, Martin LW, Ockene JK, O'Sullivan MJ, Powell LH, Simon MS, Van Horn L, Vitolins MZ, Wallace RB. Manson JE, et al. JAMA. 2013 Oct 2;310(13):1353-68. doi: 10.1001/jama.2013.278040. JAMA. 2013. PMID: 24084921 Free PMC article. Clinical Trial. - Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study.
Shumaker SA, Legault C, Kuller L, Rapp SR, Thal L, Lane DS, Fillit H, Stefanick ML, Hendrix SL, Lewis CE, Masaki K, Coker LH; Women's Health Initiative Memory Study. Shumaker SA, et al. JAMA. 2004 Jun 23;291(24):2947-58. doi: 10.1001/jama.291.24.2947. JAMA. 2004. PMID: 15213206 Clinical Trial. - Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial.
Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, Chlebowski R, Curb D, Gass M, Hays J, Heiss G, Hendrix S, Howard BV, Hsia J, Hubbell A, Jackson R, Johnson KC, Judd H, Kotchen JM, Kuller L, LaCroix AZ, Lane D, Langer RD, Lasser N, Lewis CE, Manson J, Margolis K, Ockene J, O'Sullivan MJ, Phillips L, Prentice RL, Ritenbaugh C, Robbins J, Rossouw JE, Sarto G, Stefanick ML, Van Horn L, Wactawski-Wende J, Wallace R, Wassertheil-Smoller S; Women's Health Initiative Steering Committee. Anderson GL, et al. JAMA. 2004 Apr 14;291(14):1701-12. doi: 10.1001/jama.291.14.1701. JAMA. 2004. PMID: 15082697 Clinical Trial. - New evidence regarding hormone replacement therapies is urgently required transdermal postmenopausal hormone therapy differs from oral hormone therapy in risks and benefits.
Modena MG, Sismondi P, Mueck AO, Kuttenn F, Lignières Bd, Verhaeghe J, Foidart JM, Caufriez A, Genazzani AR; TREAT. Modena MG, et al. Maturitas. 2005 Sep 16;52(1):1-10. doi: 10.1016/j.maturitas.2005.05.003. Maturitas. 2005. PMID: 15963666 Review. - Menopausal hormone therapy and breast cancer: what is the evidence from randomized trials?
Hodis HN, Sarrel PM. Hodis HN, et al. Climacteric. 2018 Dec;21(6):521-528. doi: 10.1080/13697137.2018.1514008. Epub 2018 Oct 9. Climacteric. 2018. PMID: 30296850 Free PMC article. Review.
Cited by
- Hormone therapy and the risk of stroke: perspectives 10 years after the Women's Health Initiative trials.
Henderson VW, Lobo RA. Henderson VW, et al. Climacteric. 2012 Jun;15(3):229-34. doi: 10.3109/13697137.2012.656254. Climacteric. 2012. PMID: 22612608 Free PMC article. Review. - Predicting risk of osteoporotic fracture in men and women in England and Wales: prospective derivation and validation of QFractureScores.
Hippisley-Cox J, Coupland C. Hippisley-Cox J, et al. BMJ. 2009 Nov 19;339:b4229. doi: 10.1136/bmj.b4229. BMJ. 2009. PMID: 19926696 Free PMC article. - Estrogens regulate the expression of NHERF1 in normal colon during the reproductive cycle of Wistar rats.
Cuello-Carrión FD, Troncoso M, Guiñazu E, Valdez SR, Fanelli MA, Ciocca DR, Kreimann EL. Cuello-Carrión FD, et al. Histochem Cell Biol. 2010 Dec;134(6):623-30. doi: 10.1007/s00418-010-0762-2. Epub 2010 Nov 16. Histochem Cell Biol. 2010. PMID: 21079987 - Hip fracture in postmenopausal women after cessation of hormone therapy: results from a prospective study in a large health management organization.
Karim R, Dell RM, Greene DF, Mack WJ, Gallagher JC, Hodis HN. Karim R, et al. Menopause. 2011 Nov;18(11):1172-7. doi: 10.1097/gme.0b013e31821b01c7. Menopause. 2011. PMID: 21775911 Free PMC article. - Hormonal regulation of the immune microenvironment in the mammary gland.
Need EF, Atashgaran V, Ingman WV, Dasari P. Need EF, et al. J Mammary Gland Biol Neoplasia. 2014 Jul;19(2):229-39. doi: 10.1007/s10911-014-9324-x. Epub 2014 Jul 4. J Mammary Gland Biol Neoplasia. 2014. PMID: 24993978 Review.